GlassScriptPhysician profile
Sanjay Patel
NPI 1962445528
$6,668.25
in general payments reported to CMS, 2019-2025
34 companies · $1,029 in 2025
The $1,029 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $675 · 2021: $839 · 2022: $1,191 · 2023: $700 · 2024: $1,031 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,713 · Education: $34.00 · Consulting Fee: $13.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.43 |
| Education | $34.00 |
| Consulting Fee | $13.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,929.85 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genentech USA, INC. | $771.59 | 2019-2025 | Xolair |
| Csl Behring | $714.49 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $475.80 | 2019-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $393.69 | 2019-2025 | |
| Covis Pharma Gmbh | $268.28 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $226.51 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $223.22 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $160.94 | 2019-2023 | Dupixent |
| Alk-Abello, INC | $143.53 | 2019-2024 | Alternaria Tenuis, Pre-Pen, Standardized Mite D. Farinae |
| Pfizer INC. | $132.47 | 2019-2025 | |
| Kaleo, INC. | $127.42 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $122.88 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $118.73 | 2021-2022 | |
| Amgen INC. | $106.91 | 2022-2025 | Tezspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $94.02 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.13 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.45 | 2024-2025 | Caplyta |
| Ars Pharmaceuticals Operations, INC. | $87.93 | 2025 | Neffy |
| Grifols USA, LLC | $61.49 | 2022-2023 | Prolastin-C Liquid |
| Shire North American Group INC | $50.24 | 2019 | |
| Pharming Healthcare, INC. | $46.95 | 2021-2025 | Ruconest |
| Merck Sharp & Dohme LLC | $29.12 | 2021 | |
| Uswm, LLC | $29.10 | 2021 | |
| Horizon Therapeutics Plc | $28.82 | 2020-2023 | Actimmune |
| Optinose US, INC. | $24.68 | 2020-2024 | |
| Bio Products Laboratory USA, INC. | $19.27 | 2022 | |
| Tersera Therapeutics LLC | $16.23 | 2023 | Quzyttir |
| Octapharma USA, INC. | $15.95 | 2023 | Cutaquig |
| Ionis Pharmaceuticals, INC. | $14.62 | 2025 | Dawnzera |
| Biocryst Pharmaceuticals, INC. | $13.84 | 2020 | |
| Adma Biomanufacturing LLC | $13.67 | 2025 | |
| Hikma Pharmaceuticals USA | $13.56 | 2024 | Ryaltris |
| Kedrion Biopharma, INC. | $8.87 | 2023 | Gammaked, Kedrab, Koate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.